Literature DB >> 23292737

Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation.

Jing Chen1, Can Liu, Huijuan Chen, Qicai Liu, Bin Yang, Qishui Ou.   

Abstract

BACKGROUND: Noninvasive laboratory tests have been widely used in the diagnosis of liver fibrosis. This study was designed to evaluate the diagnostic value of the four serum markers detected on a JETLIA-962 chemiluminescence analyzer and the FibroTest index for chronic hepatitis B (CHB) related liver fibrosis.
METHODS: A JETLIA-962 chemiluminescence analyzer was used to measure the hyaluronic acid (HA), laminin (LN), procollagen III N-terminal peptide (PIIINP), and type IV collagen (CIV) contents in the sera of CHB patients and controls.
RESULTS: In our research, it was found that serum HA, LN, PIIINP, and CIV concentrations and the FibroTest index were correlated with fibrosis stage. The FibroTest index had the largest area under the receiver operating characteristic (ROC) curve for fibrosis and cirrhosis (0.80 and 0.776, respectively). The five indices together were able to exclude fibrosis with a negative likelihood ratio <0.1. The logistic regression equations for diagnosing liver fibrosis and early cirrhosis were separately established.
CONCLUSIONS: We found that the JETLIA-962 chemiluminescence analyzer was of great value in diagnosis of liver fibrosis. Combining five indices improved the diagnostic efficiency and reduced the incidences of unnecessary liver biopsies. Two logistic regression equations established may be helpful in diagnosing liver fibrosis and early cirrhosis, which need to be further evaluated.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23292737      PMCID: PMC6807481          DOI: 10.1002/jcla.21554

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  13 in total

1.  Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model.

Authors:  Min-De Zeng; Lun-Gen Lu; Yi-Min Mao; De-Kai Qiu; Ji-Qiang Li; Mo-Bin Wan; Cheng-Wei Chen; Ji-Yao Wang; Xiong Cai; Chun-Fang Gao; Xia-Qiu Zhou
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

Review 2.  Noninvasive measures of liver fibrosis.

Authors:  Don C Rockey; D Montgomery Bissell
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

3.  [The guideline of prevention and treatment for chronic hepatitis B (2010 version)].

Authors: 
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2011-04

4.  [Serum fibrosis markers in diagnosing liver fibrosis].

Authors:  Jie Liu; Ji-yao Wang; Ye Lu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2006-06

5.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.

Authors:  F Imbert-Bismut; V Ratziu; L Pieroni; F Charlotte; Y Benhamou; T Poynard
Journal:  Lancet       Date:  2001-04-07       Impact factor: 79.321

6.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

7.  A novel panel of blood markers to assess the degree of liver fibrosis.

Authors:  Paul Calès; Frédéric Oberti; Sophie Michalak; Isabelle Hubert-Fouchard; Marie-Christine Rousselet; Anselme Konaté; Yves Gallois; Catherine Ternisien; Alain Chevailler; Françoise Lunel
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

8.  Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model.

Authors:  Alex Yui Hui; Henry Lik-Yuen Chan; Vincent Wai-Sun Wong; Choong-Tsek Liew; Angel Mei-Ling Chim; Francis Ka-Leung Chan; Joseph Jao-Yiu Sung
Journal:  Am J Gastroenterol       Date:  2005-03       Impact factor: 10.864

Review 9.  Diagnosis and quantitation of fibrosis.

Authors:  Diarmuid S Manning; Nezam H Afdhal
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

10.  [Noninvasive assessment of liver fibrosis in chronic hepatitis B using a predictive model].

Authors:  Wen-sheng Zhang; Bao-en Wang; Tai-ling Wang; Xiao-juan Ou; Yu Chen; Qin Li; Xiao-ming Wang; Lin-xue Qian; Hong Ma; Ji-dong Jia
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2006-03
View more
  8 in total

1.  Cardiovascular Risk and Serum Hyaluronic Acid: A Preliminary Study in a Healthy Population of Low/Intermediate Risk.

Authors:  Chrysanthi Papanastasopoulou; Maria Papastamataki; Petros Karampatsis; Eleni Anagnostopoulou; Ioannis Papassotiriou; Nikolaos Sitaras
Journal:  J Clin Lab Anal       Date:  2016-06-16       Impact factor: 2.352

2.  Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients.

Authors:  Olga Hilda Orăşan; Mădălina Sava; Mihaela Iancu; Angela Cozma; Aniela Saplonţai-Pop; Simina Sarlea Ţărmure; Corneliu Lungoci; Remus Aurel Orăşan; Ioan Mihai Patiu; Dan Lucian Dumitraşcu
Journal:  Int Urol Nephrol       Date:  2015-05-30       Impact factor: 2.370

3.  Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B.

Authors:  Xianghua Zeng; Cheng Xu; Dengming He; Maoshi Li; Huiyan Zhang; Quanxin Wu; Dedong Xiang; Yuming Wang
Journal:  Croat Med J       Date:  2015-06       Impact factor: 1.351

4.  CCN1 Promotes Inflammation by Inducing IL-6 Production via α6β1/PI3K/Akt/NF-κB Pathway in Autoimmune Hepatitis.

Authors:  Renquan Jiang; Jifeng Tang; Xuehao Zhang; Yujue He; Ziqing Yu; Shuhui Chen; Jinfang Xia; Jinpiao Lin; Qishui Ou
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

5.  Red blood cell distribution width levels correlate with liver fibrosis and inflammation: a noninvasive serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis B.

Authors:  Wen-Shen Xu; Xiao-Ming Qiu; Qi-Shui Ou; Can Liu; Jin-Piao Lin; Hui-Juan Chen; Sheng Lin; Wen-Hua Wang; Shou-Rong Lin; Jing Chen
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

6.  Potentials of the elevated circulating miR-185 level as a biomarker for early diagnosis of HBV-related liver fibrosis.

Authors:  Bin-Bin Li; Dong-Liang Li; Chao Chen; Bao-Hai Liu; Chun-Yan Xia; Han-Jun Wu; Chao-Qun Wu; Guo-Qin Ji; Su Liu; Wu Ni; Ding-Kang Yao; Zhi-Yu Zeng; Da-Gui Chen; Bao-Dong Qin; Xuan Xin; Gang-Li Yan; Hui-Min Liu; Jin He; Hongli Yan; Wei-Jian Zhu; Hong-Yu Yu; Liang Zhu
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

7.  Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B.

Authors:  Yan-Chao Hu; Hao Liu; Xiao-Yan Liu; Li-Na Ma; Yu-Hua Guan; Xia Luo; Xiang-Chun Ding
Journal:  World J Gastroenterol       Date:  2017-11-07       Impact factor: 5.742

8.  Associations of content and gene polymorphism of macrophage inhibitory factor-1 and chronic hepatitis C virus infection.

Authors:  Xun-Jun Yang; Xiao-Ou Wang; Yao Chen; Song-Dao Ye
Journal:  World J Gastroenterol       Date:  2020-11-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.